Life may have started in sticky, rock-hugging gels rather than inside cells. Researchers suggest these primitive, biofilm-like materials could trap and concentrate molecules, giving early chemistry a ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. When Kulindu Vithanachchi’s phone lit up with an update from the National Science ...

A Dalai Lama once said that our prime purpose in this life is to help others – and he may have been right. Scientists have found that having a positive impact on other people seems to be a key element ...

British Land has agreed to acquire Life Science REIT in a recommended cash-and-share deal valuing the specialist property investor at about £150M. The deal represents a premium of about 21% to Life ...

BlueRidge Life Sciences (“BlueRidge”), a leading life sciences consulting and services platform and a portfolio company of Renovus Capital Partners, today announced the acquisition of Design Science, ...

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...

After holding its breath for several rough years, Greater Boston’s life sciences sector is cautiously coming up for air. It was a year of devastating uncertainty for the sector and its roughly 75,000 ...

Caris Life Sciences has transitioned to self-funded growth with positive EBITDA and free cash flow, driven by strong MI segment performance. The Roche partnership validates CAI's discovery platform, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The developer behind ...

Life sciences dealmaking came back in 2025, and artificial intelligence is poised to drive even more M&A activity in 2026 as companies move from hyping the technology to proving its value in drug ...

The life science automation and robotics market is witnessing rapid expansion as biopharma companies accelerate their shift toward AI-driven research and automated manufacturing systems. Rising demand ...

This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's comprehensive portfolio of translational oncology services, including ...